CLBSLisata Therapeutics Inc


$ 2.78 $ -0.01 (-0.46 %)    

Friday, 26-Apr-2024 15:19:08 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 2.6478
$ 2.78
$ 0.00 x 0
$ 0.00 x 0
$ 2.78 - $ 2.78
$ 1.95 - $ 4.53
4,678
na
na
$ -1.08
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-vintage-wine-estates-shares-tumbled-40-here-are-70-biggest-movers-from-yesterday

Gainers AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resu...

 stocks-that-hit-52-week-lows-on-wednesday

  During Wednesday's session, 265 companies made new 52-week lows.

 why-scisparc-is-trading-higher-by-68-here-are-48-stocks-moving-in-wednesdays-mid-day-session

Gainers Akerna Corp. (NASDAQ: KERN) shares rose 81.2% to $0.2355 after gaining 8% on Tuesday.

 caladrius-biosciences-announces-approval-of-merger-and-name-change-to-lisata-therapeutics

BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the &...

 why-pagerduty-is-trading-higher-by-9-here-are-28-stocks-moving-premarket

Gainers

 biotech-daily-cancer-causing-impurities-in-mercks-diabetic-drug-vir-bio-gsk-shun-fda-submission-plans-for-covid-19-treatment-aethlons-monkeypox-trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

 caladrius-biosciences-prospective-merger-partner-cend-therapeutics-announces-collaboration-agreement-with-roche-to-evaluate-cend-1-in-combination-with-immunotherapy-to-treat-pancreatic-cancer

Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company") and Cend Therapeutics, Inc. ("Cend...

 caladrius-biosciences-q2-eps-011-misses-010-estimate

Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate ...

 earnings-scheduled-for-august-4-2022

  Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.

 earnings-outlook-for-caladrius-biosciences

Caladrius Biosciences (NASDAQ:CLBS) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's wha...

 caladrius-biosciencess-earnings-outlook

Caladrius Biosciences (NASDAQ:CLBS) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's wha...

 caladrius-biosciences-completes-enrollment-in-phase-1b-study-of-clbs201-for-the-treatment-of-diabetic-kidney-disease

Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical co...

 caladrius-biosciences-and-cend-therapeutics-highlights-publication-of-pancreatic-cancer-trial-data-in-the-lancet-gastroenterology-and-hepatology

Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical co...

 caladrius-biosciences-inc-ma-partner-cend-therapeutics-announces-first-patient-treated-in-phase-2b-trial-of-cend-1-led-by-australasian-gastro-intestinal-trials-group

SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. ("Cend") today announced that the first patient ha...

 the-daily-biotech-pulse-inmune-bios-planned-alzheimers-trial-on-fda-hold-caladrius-stops-enrollment-in-heart-disease-study-biomx-restructures

Here's a roundup of top developments in the biotech space over the last 24 hours:

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION